MAHA ELEVATE Part II: Should You Apply? And If Yes, Where Do You Actually Start?

Key Takeaways

• LOI due April 10; awards announced May 15.
• Program funds 30 randomized Medicare lifestyle trials.
• Success requires trial‑grade data and compliance infrastructure.
• Nutrition or activity must be included; food cannot be funded.
• CPG firms can co‑finance to gain high‑quality evidence.

Pulse Analysis

The MAHA ELEVATE program marks a pivotal shift in how the federal government approaches preventive health for seniors. By allocating $100 million to a cooperative agreement rather than a traditional grant, CMS is effectively creating a nationwide clinical‑trial network focused on lifestyle and functional‑medicine interventions. This structure forces applicants to treat their projects as research operations, complete with randomization protocols, data‑management plans, and quarterly reporting. The emphasis on generating robust, peer‑reviewed outcomes is designed to inform future Medicare coverage decisions, potentially unlocking long‑term reimbursement streams for evidence‑based nutrition and activity programs.

Competitive success will be determined by a detailed scoring rubric that rewards proven research capacity, intervention design, and administrative readiness. Organizations that already collect outcomes data, publish peer‑reviewed results, and maintain large Medicare fee‑for‑service panels are best positioned. However, the program also welcomes non‑clinical partners—such as community‑based organizations, digital health platforms, and consumer‑packaged‑goods (CPG) companies—provided they can align with a clinical partner that supplies the required trial infrastructure. This creates a fertile partnership landscape where each party contributes complementary strengths, from patient recruitment to data analytics, to meet the stringent requirements.

For the private sector, the most compelling opportunity lies in the mandated nutrition or physical‑activity component that cannot be funded directly by the grant. CPG and functional‑food firms can step in as co‑financers, embedding their products within the trial design while gaining access to high‑quality evidence that can accelerate FDA health‑claim pathways and market adoption. Early mapping of likely awardees and securing partnership agreements before the October 2026 award cycle will be critical. Applicants should prioritize building or augmenting trial‑grade data systems, finalizing randomization plans, and establishing clear co‑financing structures to maximize their chances in the tight six‑week Cohort 1 window.